Our research is centered around the neurobiological mechanisms of major depressive disorder and how these can be reversed with traditional and novel antidepressant treatment, with a specific focus on psychedelic compounds, including ketamine and psilocybin. We investigate how central processes in the brain are reflected in blood to identify markers that can be used to advance the prevention and treatment of major depressive disorder from a pathophysiological perspective. Our translational approach includes clinical research aimed at the identification and validation of blood-based biomarkers of antidepressant response and individual depressive symptoms as well as preclinical research investigating the neurobiological effects of traditional and novel antidepressant agents in both blood and brain tissue using animal models of treatment-resistant depression.
Main objectives of our research:
